Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
Future Oncol
; 8(10): 1239-51, 2012 Oct.
Article
em En
| MEDLINE
| ID: mdl-23130925
ABSTRACT
Clusterin is a stress-induced cytoprotective chaperone that confers broad-spectrum treatment resistance and is overexpressed across a number of cancers. custirsen (OGX-011) is a promising novel second-generation antisense inhibitor of clusterin in clinical development. This article describes the mechanism of action and safety profile of OGX-011 and details the Phase I and II results in human solid organ malignancies. Two Phase III registration trials are currently under recruitment evaluating OGX-011 in combination with chemotherapy in patients with metastatic castration-resistant prostate cancer. These studies not only have the potential to significantly alter the standard of care in prostate cancer, but would also endorse a new class of targets and targeted therapy approach for cancer.
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Prostata
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Tionucleotídeos
/
Oligonucleotídeos Antissenso
/
Clusterina
Limite:
Humans
/
Male
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Canadá